US3450502A - Method of operating heart-lung apparatus - Google Patents
Method of operating heart-lung apparatus Download PDFInfo
- Publication number
- US3450502A US3450502A US670395A US3450502DA US3450502A US 3450502 A US3450502 A US 3450502A US 670395 A US670395 A US 670395A US 3450502D A US3450502D A US 3450502DA US 3450502 A US3450502 A US 3450502A
- Authority
- US
- United States
- Prior art keywords
- ethylene oxide
- molecular weight
- heart
- solution
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3643—Priming, rinsing before or after use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3643—Priming, rinsing before or after use
- A61M1/3644—Mode of operation
Definitions
- the present invention relates to an improved method of operating the heart-lung apparatus. More particularly, the present invention relates to the use of certain solutions of ethylene oxide-polypropylene glycol condensation products as priming agents in the heart-lung apparatus.
- the heart-lung apparatus is an instrument which permits surgeons to by-pass both the heart and the lungs during operations.
- the instrument comprises two essential components, a pump and an oxygenator.
- the function of the instrument is to oxygenate and withdraw carbon dioxide from blood and to pump this blood into the arteries, thus substituting for both the heart and the lungs.
- the heart-lung apparatus Prior to patient hook-up, the heart-lung apparatus is primed with enough fluid to fill all working chambers, reservoirs, and tubing in the patient. Historially, blood plasma was employed as a priming agent for the heartlung apparatus.
- the art has long been in need of a material which will perform as a substitute therefor.
- a material To be useful as a blood plasma substitute, a material must possess the following properties: 1) it must retain a sufficient molecular size to remain in the blood space, thus creating an osmotic pres sure great enough to retain the solvent (water) within the circulation, (2) it must be miscible with blood, (3) it must be non-antigenic, non-toxic, and non-pyretogenic, (4) it must not draw water from the cellular area of the body, (5) it must be readily available and stable under prolonged storage conditions, and (6) when no longer needed, it must be readily discharged from the body circulation. With such daunting requirements, it is little wonder that the art has not heretofore found any material which satisfactorily performs as a blood plasma substitute.
- the process of the present invention comprises the improvement in the operation of the heartlung apparatus which comprises employing as a priming agent therefor an isotonic (isosmotic) solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to 90% by weight of the compound.
- isotonic or isosmotic solution is meant a solution having the same osmotic pressure as blood. This phrase is well known in the art.
- Illustrative soliutions which may be employed in the preparation of the blood plasma substitutes employed in the process of the present invention include saline (a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water), Ringers solution, Ringers lactated solution, Krebs- Ringers solution, and various sugar solutions.
- saline a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
- Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
- Ringers solution Ringers lactated solution
- Krebs- Ringers solution a sugar solutions.
- the isotonic solutions useful in the present invention will comprise from 0.375 to 1.5 millimoles/liter of the abovementioned ethylene oxide-polypropylene glycol condensation products. Compositions comprising amounts of products outside of the above-cited range have been found to be unacceptable blood plasma substitutes.
- the condensation products which are operable in the present invention are prepared by condensing ethylene oxide with polypropylene glycol. A more detailed discussion of the preparation of these products is found in U.S. 2,674,619.
- the products must contain at least 50% by weight of ethylene oxide.
- the polyproylene glycol base must have a molecular weight of at least 950. It has been determined that products outside of these limits are not satisfactory blood plasma substitutes for various reasons. For example, a product containing less than 50% ethylene oxide is not sufficiently non-toxic to be useful whereas a product containing a hydrophobic base molecular Weight of less than about 950 has completely different physio-a1 properties, particularly with regard to solubility, than the products useful in the present invention.
- Illustrative ethylene oxide-polypropylene glycol condensation products which may be employed in the preparation of the isotonic solutions useful in the present invention include:
- Example I An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in Ringers lactated (0.513 millimoles/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then employed as a priming agent in the heart-lung apparatus in the manner described in an article by A. C. Hymes, N. Norimotf, and A. P. Thal, entitled A Comparison Between Mannitol Solutions and Low Molecular Weight Dextran as a Perfusate in Extracorporeal Circulation, Surgery, 59: 414-420, March 1966.
- Example H A solution containing 1.0 millimole/liter of a polyol having a molecular weight of about 16,250 and containing approximately 80% ethylene oxide prepared by the reaction of ethylene oxide with a polypropylene glycol having a molecular weight of 3250 was prepared by dissolving 16.25 grams of said polyol in liters of saline solution containing 9 grams of sodium chloride in 1000 cc. of water. The solution was then employed as a priming agent in the heart-lung apparatus as described in Example I. Of the ten dogs treated, nine survived. In addition, no adverse effects were noticed in the surviving dogs.
- the improvement in the method of operating the heart-lung apparatus which comprises employing as priming agent therefor, an isotonic solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of from 1750 to 4000 and b is an integer such that the hydrophile portion represented by (CZHQO) constitutes by weight of the compound.
- the isotonic solution comprises from 0.375 to 1.5 millimoles per liter of lactated Ringers solution of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to by weight of the compound.
- the isotonic solution comprises from 0.375 to 1.5 millimoles per liter of saline solution of a compound of the formula 2 4 )b( a s )a( 2 4. )b wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H.,O) constitutes from about 50% to 90% by weight of the compound.
Description
United States Patent U.S. Cl. 23-258.5 4 Claims ABSTRACT OF THE DISCLOSURE Isotonic solutions of certain ethylene oxide-polypropylene glycol condensation products have been found to be extremely effective as priming agents in the heart-lung apparatus.
The present invention relates to an improved method of operating the heart-lung apparatus. More particularly, the present invention relates to the use of certain solutions of ethylene oxide-polypropylene glycol condensation products as priming agents in the heart-lung apparatus.
The heart-lung apparatus is an instrument which permits surgeons to by-pass both the heart and the lungs during operations. The instrument comprises two essential components, a pump and an oxygenator. The function of the instrument is to oxygenate and withdraw carbon dioxide from blood and to pump this blood into the arteries, thus substituting for both the heart and the lungs. Prior to patient hook-up, the heart-lung apparatus is primed with enough fluid to fill all working chambers, reservoirs, and tubing in the patient. Historially, blood plasma was employed as a priming agent for the heartlung apparatus. However, because of the high cost, scarcity and storage problems of blood plasma, the art has long been in need of a material which will perform as a substitute therefor. To be useful as a blood plasma substitute, a material must possess the following properties: 1) it must retain a sufficient molecular size to remain in the blood space, thus creating an osmotic pres sure great enough to retain the solvent (water) within the circulation, (2) it must be miscible with blood, (3) it must be non-antigenic, non-toxic, and non-pyretogenic, (4) it must not draw water from the cellular area of the body, (5) it must be readily available and stable under prolonged storage conditions, and (6) when no longer needed, it must be readily discharged from the body circulation. With such formidable requirements, it is little wonder that the art has not heretofore found any material which satisfactorily performs as a blood plasma substitute. This is so notwithstanding the fact that various materials such as salt solutions, gelatin derivatives, various proteins and derivatives thereof, mannitol, starch and dextrans have been investigated as blood plasma substitues. However, these materials all lack one or more of the above requirements, thereby rendering them not totally acceptable as blood plasma substitutes.
Now, in accordance with the present invention, it has been determined that certain solutions of ethylene oxidepolypropylene glycol condensation products may be effectively employed as priming agents in the heart-lung apparatus. It has been determined that by the process of the present invention, prolonged extracorporeal circulation may be carried out without any significant adverse effects. Thus, the process of the present invention comprises the improvement in the operation of the heartlung apparatus which comprises employing as a priming agent therefor an isotonic (isosmotic) solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to 90% by weight of the compound. By the phrase isotonic or isosmotic solution is meant a solution having the same osmotic pressure as blood. This phrase is well known in the art. Illustrative soliutions which may be employed in the preparation of the blood plasma substitutes employed in the process of the present invention include saline (a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water), Ringers solution, Ringers lactated solution, Krebs- Ringers solution, and various sugar solutions.
As stated above, critical amounts of certain ethylene oxide-polypropylene glycol condensation products must be employed in the preparation of the blood plasma substitutes useful in the present invention. Generally, the isotonic solutions useful in the present invention will comprise from 0.375 to 1.5 millimoles/liter of the abovementioned ethylene oxide-polypropylene glycol condensation products. Compositions comprising amounts of products outside of the above-cited range have been found to be unacceptable blood plasma substitutes.
The condensation products which are operable in the present invention are prepared by condensing ethylene oxide with polypropylene glycol. A more detailed discussion of the preparation of these products is found in U.S. 2,674,619. To be useful in the present invention, the products must contain at least 50% by weight of ethylene oxide. Furthermore, the polyproylene glycol base must have a molecular weight of at least 950. It has been determined that products outside of these limits are not satisfactory blood plasma substitutes for various reasons. For example, a product containing less than 50% ethylene oxide is not sufficiently non-toxic to be useful whereas a product containing a hydrophobic base molecular Weight of less than about 950 has completely different physio-a1 properties, particularly with regard to solubility, than the products useful in the present invention.
Illustrative ethylene oxide-polypropylene glycol condensation products which may be employed in the preparation of the isotonic solutions useful in the present invention include:
(1) 4750 molecular weight polyol containing approximately by weight ethylene oxide,
(2) 3500 molecular weight polyol containing approximately 5 0% by weight ethylene oxide,
(3) 7800 molecular weight polyol containing approximately 80% by weight ethylene oxide,
(4) 7500 molecular weight polyol containing approxi mately 70% by weight ethylene oxide,
(5) 16,250 molecular weight polyol containing approximately 80% by weight ethylene oxide,
6) 13,330 molecular weight polyol containing approximately 70% by Weight ethylene oxide,
(7) 9500 molecular weight polyol containing approximately by weight ethylene oxide.
The following examples illustrate the nature of the invention. All parts are by weight unless otherwise stated.
Example I An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in Ringers lactated (0.513 millimoles/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then employed as a priming agent in the heart-lung apparatus in the manner described in an article by A. C. Hymes, N. Norimotf, and A. P. Thal, entitled A Comparison Between Mannitol Solutions and Low Molecular Weight Dextran as a Perfusate in Extracorporeal Circulation, Surgery, 59: 414-420, March 1966.
Of the 29 dogs perfused with the above solution, 27 survived (93% survival) without complications. Perfusion flow rates were high, and arterial blood pH one hour postperfusion was normal (7.33:0.06). Urine production was unimpaired during and following perfusion. Plasma hemoglobin was low and averaged 30 mg. percent. Fifteen minutes post-perfusion blood volume was only 8% greater than the initial blood volume before perfusion. Following this procedure, all of the fluid within the heartlung apparatus (now mixed with blood) was returned to the animal. The high flow rates during perfusion indicate that the osmotic pressure of the solute (polyol) was great enough to retain the solvent (water) within the vascular space during the procedure.
Example H A solution containing 1.0 millimole/liter of a polyol having a molecular weight of about 16,250 and containing approximately 80% ethylene oxide prepared by the reaction of ethylene oxide with a polypropylene glycol having a molecular weight of 3250 was prepared by dissolving 16.25 grams of said polyol in liters of saline solution containing 9 grams of sodium chloride in 1000 cc. of water. The solution was then employed as a priming agent in the heart-lung apparatus as described in Example I. Of the ten dogs treated, nine survived. In addition, no adverse effects were noticed in the surviving dogs.
What is claimed is:
1. The improvement in the method of operating the heart-lung apparatus which comprises employing as priming agent therefor, an isotonic solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of from 1750 to 4000 and b is an integer such that the hydrophile portion represented by (CZHQO) constitutes by weight of the compound.
3. The method of claim 1 wherein the isotonic solution comprises from 0.375 to 1.5 millimoles per liter of lactated Ringers solution of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to by weight of the compound.
4. The method of claim 1 wherein the isotonic solution comprises from 0.375 to 1.5 millimoles per liter of saline solution of a compound of the formula 2 4 )b( a s )a( 2 4. )b wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of at least 950 and b is an integer such that the hydrophile portion represented by (C H.,O) constitutes from about 50% to 90% by weight of the compound.
References Cited MORRIS O. WOLK, Primary Examiner.
BARRY S. RICHMAN, Assistant Examiner.
US. Cl. X.R.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67039567A | 1967-09-25 | 1967-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3450502A true US3450502A (en) | 1969-06-17 |
Family
ID=24690235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US670395A Expired - Lifetime US3450502A (en) | 1967-09-25 | 1967-09-25 | Method of operating heart-lung apparatus |
Country Status (1)
Country | Link |
---|---|
US (1) | US3450502A (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US3880989A (en) * | 1973-01-30 | 1975-04-29 | Baxter Laboratories Inc | Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer |
US3893990A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
US3893991A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US3956259A (en) * | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
US4025500A (en) * | 1974-06-06 | 1977-05-24 | Baxter Laboratories, Inc. | Preparation of albumin by fractionation of blood plasma or serum |
US4073886A (en) * | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
US4164524A (en) * | 1974-05-31 | 1979-08-14 | Ward Charles A | Treatment of blood containing vessels |
US4506018A (en) * | 1982-12-30 | 1985-03-19 | Becton, Dickinson And Company | Blood diluent |
US4801452A (en) * | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
US4837014A (en) * | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
US4873083A (en) * | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US4937070A (en) * | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US4938961A (en) * | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
US4997644A (en) * | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
US5017370A (en) * | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
US5028599A (en) * | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5032394A (en) * | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5047236A (en) * | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
US5064643A (en) * | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5078995A (en) * | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
US5080894A (en) * | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
US5089260A (en) * | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
US5240701A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of performing angioplasty procedures |
US5250294A (en) * | 1986-05-15 | 1993-10-05 | Emory University | Improved perfusion medium for transplantation of organs |
WO1995012310A1 (en) * | 1993-11-02 | 1995-05-11 | Emory University | Composition for tissue and organ transplantation preservation |
US5523492A (en) * | 1991-03-19 | 1996-06-04 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5536427A (en) * | 1991-10-23 | 1996-07-16 | Sodick Co., Ltd. | Non-flammable electric discharge machining fluid including a block copolymer |
US5622649A (en) * | 1991-06-27 | 1997-04-22 | Emory University | Multiple emulsions and methods of preparation |
US5648071A (en) * | 1986-05-15 | 1997-07-15 | Emory University | Method of treating tumors |
US5658560A (en) * | 1994-01-18 | 1997-08-19 | Serikov; Vladimir B. | Method of treating endotoxemia by administering tyloxapol |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
US5696298A (en) * | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
USRE38558E1 (en) | 1991-03-19 | 2004-07-20 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US20040248833A1 (en) * | 1991-03-19 | 2004-12-09 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US7202225B1 (en) | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2674619A (en) * | 1953-10-19 | 1954-04-06 | Wyandotte Chemicals Corp | Polyoxyalkylene compounds |
US2677700A (en) * | 1951-05-31 | 1954-05-04 | Wyandotte Chemicals Corp | Polyoxyalkylene surface active agents |
US3396849A (en) * | 1966-05-10 | 1968-08-13 | Univ Minnesota | Membrane oxygenator-dialyzer |
-
1967
- 1967-09-25 US US670395A patent/US3450502A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2677700A (en) * | 1951-05-31 | 1954-05-04 | Wyandotte Chemicals Corp | Polyoxyalkylene surface active agents |
US2674619A (en) * | 1953-10-19 | 1954-04-06 | Wyandotte Chemicals Corp | Polyoxyalkylene compounds |
US3396849A (en) * | 1966-05-10 | 1968-08-13 | Univ Minnesota | Membrane oxygenator-dialyzer |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US3880989A (en) * | 1973-01-30 | 1975-04-29 | Baxter Laboratories Inc | Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer |
US3956259A (en) * | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
US4073886A (en) * | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
US3893990A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
US3893991A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4164524A (en) * | 1974-05-31 | 1979-08-14 | Ward Charles A | Treatment of blood containing vessels |
US4025500A (en) * | 1974-06-06 | 1977-05-24 | Baxter Laboratories, Inc. | Preparation of albumin by fractionation of blood plasma or serum |
US4506018A (en) * | 1982-12-30 | 1985-03-19 | Becton, Dickinson And Company | Blood diluent |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5047236A (en) * | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
US4873083A (en) * | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US4937070A (en) * | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US4837014A (en) * | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
US5250294A (en) * | 1986-05-15 | 1993-10-05 | Emory University | Improved perfusion medium for transplantation of organs |
US4997644A (en) * | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
US5017370A (en) * | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
US5028599A (en) * | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5032394A (en) * | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5648071A (en) * | 1986-05-15 | 1997-07-15 | Emory University | Method of treating tumors |
US5064643A (en) * | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
US4801452A (en) * | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
US5078995A (en) * | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
US5080894A (en) * | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
US5089260A (en) * | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US5240701A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of performing angioplasty procedures |
US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
WO1990013307A1 (en) * | 1989-04-28 | 1990-11-15 | Waters Instruments, Inc. | Organ preservation solution and method |
US4938961A (en) * | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
US5691387A (en) * | 1991-03-19 | 1997-11-25 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
USRE38558E1 (en) | 1991-03-19 | 2004-07-20 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US20040248833A1 (en) * | 1991-03-19 | 2004-12-09 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US5523492A (en) * | 1991-03-19 | 1996-06-04 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US6747064B2 (en) | 1991-03-19 | 2004-06-08 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5696298A (en) * | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US6359014B1 (en) | 1991-03-19 | 2002-03-19 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5990241A (en) * | 1991-03-19 | 1999-11-23 | Cytrx, Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
USRE36665E (en) * | 1991-03-19 | 2000-04-18 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
USRE37285E1 (en) | 1991-03-19 | 2001-07-17 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
US5622649A (en) * | 1991-06-27 | 1997-04-22 | Emory University | Multiple emulsions and methods of preparation |
WO1993003738A1 (en) * | 1991-08-14 | 1993-03-04 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5536427A (en) * | 1991-10-23 | 1996-07-16 | Sodick Co., Ltd. | Non-flammable electric discharge machining fluid including a block copolymer |
US7202225B1 (en) | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
WO1995012310A1 (en) * | 1993-11-02 | 1995-05-11 | Emory University | Composition for tissue and organ transplantation preservation |
US5658560A (en) * | 1994-01-18 | 1997-08-19 | Serikov; Vladimir B. | Method of treating endotoxemia by administering tyloxapol |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3450502A (en) | Method of operating heart-lung apparatus | |
US3590125A (en) | Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes | |
US3577522A (en) | Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes | |
US4927623A (en) | Dissolution of gas in a fluorocarbon liquid | |
US5439882A (en) | Blood substitute | |
FI81008B (en) | FLYTANDE BLANDNING FOER MOTTAGNING OCH STABILIZERING AV GASBUBBLOR FOER ANVAENDNING SOM KONTRASTMEDEL VID ULTRALJUDDIAGNOSTIK. | |
US5114932A (en) | Hyperosmolar oxyreplete hemosubstitute | |
JP2000516196A (en) | Composition comprising PVP having an average molecular weight of 3,000 to 14,000 daltons | |
JPH04505119A (en) | Histidine-buffered peritoneal dialysis solution | |
MYERS et al. | Causes of necrosis in pedicle flaps | |
Solanke | Clinical trial of 6% hydroxyethyl starch (a new plasma expander) | |
JP2022145712A (en) | Organ preservation and/or perfusion solution | |
AU650439B2 (en) | Polyhemoglobin stabilized by purine derivatives and glutathione | |
McMillan et al. | Experience with three Brescia–Cimino shunts | |
JPH02304026A (en) | Liquid for peritoneal lavage | |
Nuutinen et al. | The effect of dipyridamole on the thrombocyte count and bleeding tendency in open-heart surgery | |
RU2413502C1 (en) | Asn-bokeriya-boldyrev cardioplegic solution | |
Mustard et al. | Clinical experience with the artificial heart lung preparation | |
US6218099B1 (en) | Methods and compositions for use in perfusion applications | |
JP3174400B2 (en) | Peritoneal washings | |
Estrin et al. | A new approach to massive blood transfusion during pediatric liver resection | |
Campbell et al. | Maintenance of respiratory function with isolated lung lobes during cardiac inflow occlusion. | |
JP3008354B2 (en) | Blood additive composition used for extracorporeal blood circulation device | |
IL30719A (en) | Physiological salt solutions of ethylene oxidepolypropylene glycol condensation products | |
JP2001204809A (en) | Blood-compatible composition, and medical instrument coated with same |